Published in World J Gastroenterol on June 07, 2010
CD73 is critical for the resolution of murine colonic inflammation. J Biomed Biotechnol (2012) 0.97
Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol (2011) 0.94
Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
What is the impact of age on adult patients with inflammatory bowel disease? Clujul Med (2013) 0.77
Prediction of disease course in inflammatory bowel diseases. World J Gastroenterol (2010) 0.76
Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. Medicine (Baltimore) (2015) 0.75
Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target. Therap Adv Gastroenterol (2017) 0.75
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 7.27
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Predictors of Crohn's disease. Gastroenterology (2006) 3.96
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology (2000) 3.84
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 3.49
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut (2005) 3.31
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78
Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology (2002) 2.71
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology (2005) 2.70
Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol (2007) 2.68
Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol (2006) 2.61
Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology (1996) 2.61
Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology (2008) 2.52
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol (2008) 2.44
Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol (2007) 2.34
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol (2009) 2.12
Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol (2008) 2.09
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut (2008) 2.06
Predicting outcome in severe ulcerative colitis. Gut (1996) 1.99
Smoking in Crohn's disease: effect on localisation and clinical course. Gut (1992) 1.87
Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology (1990) 1.79
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol (2009) 1.77
A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis (2006) 1.70
Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology (2006) 1.69
Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol (2006) 1.68
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut (2007) 1.64
Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol (2004) 1.64
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc (1996) 1.61
Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol (2008) 1.52
Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol (2002) 1.49
Predictors of severe Crohn's disease. Scand J Gastroenterol (2008) 1.47
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis (2006) 1.44
Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol (2007) 1.43
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol (2009) 1.36
Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? World J Gastroenterol (2006) 1.35
Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol (2004) 1.34
The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis (2008) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol (2007) 1.32
The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol (1988) 1.31
Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut (2005) 1.30
The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol (2009) 1.29
Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther (1999) 1.27
New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol (2007) 1.27
Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis (2008) 1.26
Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child (1995) 1.21
Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology (2005) 1.20
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am J Gastroenterol (2003) 1.19
Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol (2009) 1.19
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology (2008) 1.19
Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol (2009) 1.19
Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol (2007) 1.15
Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology (2000) 1.13
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis (2007) 1.05
The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci (2006) 1.05
The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci (2007) 1.04
Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis (2009) 1.03
Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis (2010) 1.03
Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis (2009) 0.92
Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther (2005) 0.90
Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis (2003) 0.89
Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol (2010) 0.88
Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol (2009) 0.82
Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion (2006) 0.81
DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. Inflamm Bowel Dis (2006) 0.80
Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis (2013) 2.18
Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol (2012) 1.89
IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis (2010) 1.20
Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis (2011) 1.09
NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. World J Gastroenterol (2010) 0.87
Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion (2012) 0.83
Is early limited surgery associated with a more benign disease course in Crohn's disease? World J Gastroenterol (2013) 0.83
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis (2010) 0.82
Recommendations for identifying Crohn's disease patients with poor prognosis. Expert Rev Clin Immunol (2013) 0.82
The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis (2012) 0.80
Risk of colorectal cancer in Crohn's disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary. J Gastrointestin Liver Dis (2013) 0.79
[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease]. Orv Hetil (2010) 0.78
Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
[The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron's disease, in Veszprém county, Hungary, a population-based cohort study]. Orv Hetil (2012) 0.78
Nutritional influences in selected gastrointestinal diseases. Dig Dis (2011) 0.77
Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008. J Crohns Colitis (2010) 0.77
Methotrexate: should we start using it in clinical practice? Curr Drug Targets (2013) 0.76